Glucotrack, Inc. (NASDAQ: GCTK) announced on September 24, 2026, the pricing of a public offering of common stock and pre-funded warrants. The company entered into a securities purchase agreement with certain institutional investors to sell an aggregate of 169,388 shares of common stock and pre-funded warrants. The offering price per share is $2.04, while the price per pre-funded warrant is $2.039.
The pre-funded warrants allow the holder to purchase up to 1,350,220 shares of common stock. The offering is expected to close on or about September 25, 2026, subject to customary closing conditions. The company has engaged Dawson James Securities, Inc. as the sole placement agent for the transaction.
Glucotrack expects to receive aggregate gross proceeds of approximately $3.1 million, before deducting placement agent fees and other offering expenses. The company intends to use the net proceeds from the offering to pay off existing debt, with the remainder allocated to working capital and general corporate purposes.
Under the terms of the purchase agreement, the company has agreed to a six-month lock-up period following the closing of the offering. This restriction prohibits the company from issuing additional shares of common stock or common stock equivalents, other than those covered by an existing registration statement on Form S-3 (File No. 333-282297), for a period of six months. Additionally, the company and its directors and executive officers have entered into lock-up agreements that restrict the sale of their shares for 90 days after the filing of the final prospectus.
